The price of Calquence 100 mg capsules can vary significantly depending on factors such as insurance coverage, pharmacy, and location. While specific price lists are not publicly available, a typical cash price for a 30-day supply can range from approximately $15,000 to over $17,000 [1].
How much does a Calquence prescription typically cost?
A prescription for Calquence, which is used to treat certain types of blood cancer, can be expensive for patients without adequate insurance. The cost is generally for a 30-day supply of the medication.
What options are available to help reduce the cost of Calquence?
For eligible patients, AstraZeneca, the manufacturer of Calquence, offers a co-pay assistance program [2]. This program can help reduce out-of-pocket expenses for commercially insured patients. Information about this program and eligibility requirements can be found on the Calquence website or by contacting AstraZeneca customer service.
When does the patent for Calquence expire?
The patent landscape for Calquence is complex, involving multiple patents protecting different aspects of the drug. As of early 2024, the core patents for Calquence (acalabrutinib) are generally expected to expire in the late 2030s, with some key patents expiring around 2035 [3]. However, additional patents, including those related to formulations or methods of use, may extend market exclusivity. DrugPatentWatch.com tracks these patent expirations for acalabrutinib [3].
Can generic versions of Calquence be made available?
Generic versions of Calquence can only be manufactured and marketed after the relevant patents expire and any applicable regulatory exclusivities have ended. The exact timeline for the availability of generic acalabrutinib will depend on the expiration dates of all relevant patents and any successful patent challenges.
What is Calquence used to treat?
Calquence (acalabrutinib) is a medication approved for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [4]. It is also approved for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [4].
How does Calquence work?
Calquence is a type of targeted therapy known as a Bruton's tyrosine kinase (BTK) inhibitor [4]. By inhibiting BTK, it interferes with signaling pathways that are important for the growth and survival of certain B-cells, including cancerous B-cells [4].
Sources:
1. GoodRx
2. Calquence Co-Pay Savings Card
3. DrugPatentWatch - Acalabrutinib
4. Calquence Prescribing Information